Human IgG4 Isotype Control Antibody (CAT#: MOB-0408ZL)
Recombinant Human IgG4 monoclonal antibody specifically binds to a hapten that is not expressed in mammalian cells.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
Figure 1 Human IgG4 Isotype Control Antibody (MOB-0408ZL) in SDS-PAGE
SDS-PAGE analysis of MOB-0408ZL in reduced (lane 1) and non-reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.
The purity of MOB-0408ZL was greater than 95% as determined by SDS-PAGE.
Specifications
- Immunogen
- Hapten molecule not expressed in mammalian cells
- Host Species
- Human
- Type
- Human IgG4, κ
- Clone
- FU015
- Applications
- ELISA, IB, FC, IHC, FuncS
Product Property
- Purification
- Affinity chromatography purified.
- Purity
- >95% as determined by analysis by SDS-PAGE
- Format
- Liquid
- Concentration
- 1.0 mg/ml
- Buffer
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test.
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- IGHG4; immunoglobulin heavy chain constant region gamma 4
Related Resources
Choi, Seong Jin, et al. "KIR+ CD8+ and NKG2A+ CD8+ T cells are distinct innate-like populations in humans." Cell Reports 42.3 (2023). https://doi.org/10.1016/j.celrep.2023.112236
This study explores the heterogeneity among human KIR+CD8+ and NKG2A+CD8+ T cells, identifying them as distinct innate-like populations with different cytokine responsiveness. The research demonstrates that KIR+CD8+ T cells exhibit IL-15-induced NK-like cytotoxicity, while NKG2A+CD8+ T cells show IL-12/IL-18-induced IFN-gamma production. It was observed that KIR+CD8+ T cells are more terminally differentiated and replicative senescent compared to NKG2A+CD8+ T cells, which are more responsive to IL-12 and IL-18 due to the high expression of these receptors induced by the transcription factor PLZF.
At Creative Biolabs, we provided essential reagents for this study, including the anti-NKG2A antibody (Cat#: TAB-437CQ) and the IgG4 isotype control (Cat# MOB-0408ZL) used in the flow cytometry analyses. Our products were crucial in identifying the distinct functional roles and cytokine responses of these T cell subsets. This research underscores the importance of understanding the diverse functions of T cell populations in developing targeted immunotherapies, highlighting our commitment to advancing immunological research and innovative therapeutic solutions.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
Customer Reviews and Q&As
Excellent for IgG4 Control
Reliable in Immunoassays
Consistent and High-Quality
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# MOB-0408ZL, RRID: AB_3111477)
Popular products with customers
Application: ELISA, Neut, IF, IP, FC, FuncS
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: ELISA
Application: WB, ELISA, FC, IHC, IP
Application: FC, FRET, Internalization
Application: ELISA, IHC, FC, IP, IF, Inhib
Application: ELISA, FC, IF, IHC, WB
Application: ELISA, WB
Application: ELISA, IHC, IF, IP
For Research Use Only. Not For Clinical Use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.